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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 2-2.5 hours of work and is not intended to be a comprehensive 
summary of evidence. 
The need to avoid COVID-19 stigma: lessons from TB response 
Ro, C. | Forbes | 1 April 2020 | Blog 
Stigma against TB excludes people and makes them less likely to approach healthcare reducing 
prevention measures and increasing possible spread. Stigma against COVID-19 has already 
shown with terms like “Chinese flu” and “super spreaders”. People with TB are vulnerable to 
COVID-19 with similar initial symptoms. There are opportunities for treating and preventing both 
of these respiratory diseases. Reducing poverty and overcrowding and increasing hygiene will 
reduce the spread of both infections and simultaneous testing for both diseases in countries with 
high TB rates may become available. Stigma discrimination must be stopped early. 
From PREDICT to prevention, one pandemic later 
Carlson, C.J. | The Lancet Microbe | 31 March 2020 | Comment 
https://doi.org/10.1016/S2666-5247(20)30002-1 
To prevent future pandemics and build on the US$207 million foundation of PREDICT, the last-
standing USAID Emerging Pandemic Threats funding programme which supported a decade of 
virology, ecology, and epidemiology around the world and which ended only a few weeks before 
the SARS-CoV-2 pandemic, collaboration is needed among disease ecologists, wildlife virologists, 
and data scientists to develop models that integrate new data streams and more complex 
virological data to develop the next generation of zoonotic risk assessment tools that might first 
identify and highlight future threats before the first human infection. 
Urgent call for an exit plan: the economic and social consequences of responses to 
COVID-19 pandemic 
Sullivan, R and Chalkidou, K | Center for Global Development | 31 March 2020 | Blog 
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https://www.cgdev.org/blog/urgent-call-exit-plan-economic-and-social-consequences-responses-
covid-19-pandemic 
Authors call for the following recommendations and policy changes (1) rapid scale up of testing for 
SARS-CoV-2 and antibodies to symptomatic population and healthcare workers; (2) re-evaluation 
of communication strategy; (3) rethink of critical planning for pandemics; and (4) development of 
an urgent exit plan. Lessons should have been learnt from over 20 epidemics and pandemics over 
the last decade to have been better prepared. Consequences of responding to COVID-19, 
including social distancing and lockdown policies, will go beyond just health outcomes. The World 
Bank estimate that nearly 24 million fewer people will escape poverty across developing East Asia 
Pacific in 2020 than would have in the absence of the pandemic. The Economic Commission for 
Africa have warned that COVID-19 could lead to Africa’s export revenues from fuels falling, 
remittances and tourism affected, job losses, price increase and availability decrease of 
pharmaceuticals largely imported from Europe and an impact on food availability and food security 
given nearly two-thirds of African countries being net importers of basic food. The intra-African 
market could help mitigate some of these effects by taking advantage of trading with the African 
Continental Free Trade Area when is commences, limiting dependence on external partners.  
Financing and scaling innovation for the COVID fight: a closer look at demand-side 
incentives for a vaccine 
Silverman, R et al. | Center for Global Development | 31 March 2020 | Notes 
https://www.cgdev.org/sites/default/files/Silverman-Krubiner-Chalkidou-Towse-R%26D-
COVID.pdf 
This note calls for consideration of demand-side options for de-risking the market, to put in place 
appropriate, coordinated advance funding that can incentivise private sector development and 
delivery at scale of high-quality vaccines against COVID-19 while ensuring that access of 
populations from LICs through commitments on price, investment in additional manufacturing 
capacity and funding to support procurement. Whilst this note focusses on COVID-19, authors 
offer this opportunity for governments to think about other emerging and yet unknown pathogens, 
including novel viruses and drug resistant bacteria, to put in place responsive, resilient, fit-for 
purpose systems for high-value innovation and scale-up. Additionally, how LMIC governments can 
use demand side incentives to proactively tackle current health challenges including TB and HIV. 
Ensuring global access to COVID-19 vaccines 
Yamey et al | The Lancet | 31 March 2020 | Comment 
https://doi.org/10.1016/S0140-6736(20)30763-7 
This Comment warns against high-income countries monopolising the supply of COVID-19 
vaccines. This has been learnt from the 2009 influenza A/H1N1 pandemic where rich countries 
negotiated large advance orders for the vaccine, crowding out poor countries. Whilst there is a 
global need for COVID-19 vaccines, albeit differentially across populations, there must be the 
opportunity of initially scare resources to be prioritised for healthcare workers and people at 
greatest risk of severe illness and death irrespective of country income. The authors suggest a 
solution - for governments to ensure there is a globally fair allocation system. This system, using 
existing instruments and institutions, would require a global purchasing agent or agents, a 
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substantial but limited-term advanced purchase commitment, and access through the system to 
financial instruments such as concessional loans or grants and indemnification from liability to 
offset the risks taken by participating private sector partners. Vaccines purchased should be free 
at the point of care for prioritised populations anywhere. 
Refugee and migrant health in the COVID-19 response 
Kluge et al. | The Lancet | 31 March 2020 | Comment 
https://doi.org/10.1016/S0140-6736(20)30791-1 
Preparedness plans should consider refugees and migrants in camps and in the wider community. 
Their needs must be included in national public health systems, with no risk of financial or legal 
consequences for them. Refugees and migrants are potentially at increased risk of contracting 
diseases, including COVID-19, for multiple reasons including overcrowded conditions, lack of 
access to basic sanitation, poor access to healthcare services including health information and 
typically face administrative, financial, legal and language barriers to access the health system. In 
camps, basic public health measures will be difficult to implement. Site-specific epidemiological 
COVID-19 risk assessments must be done, case management protocols and rapid deployment of 
outbreak response teams if needed. International migrant workers and refugees can be affected 
by income loss, healthcare insecurity and consequences of postponement of decisions on their 
legal status. COVID-19 pandemic emergency and lockdowns have affected volunteer community 
service provision for refuges and migrants. Furthermore, stigmatisation and discrimination against 
this population for spreading disease risks wider public health outcomes, including for host 
populations, since they could be fearful to seek treatment or disclose symptoms.  
LSHTM teams up with UK Government and Unilever to reach a billion people in global 
handwashing campaign 
LSHTM | 30 March 2020 | News 
https://www.lshtm.ac.uk/newsevents/news/2020/lshtm-teams-uk-government-and-unilever-reach-
billion-people-global-handwashing 
This programme will reach up to a billion people globally aiming to raise awareness and change 
behaviour to ensure people are washing their hands with soap regularly. Also, the programme will 
provide more than 20 million hygiene products in developing countries, including in areas where 
there is little or no sanitation. 
Ethical standards for research during public health emergencies: Distilling existing 
guidance to support COVID-19 R&D  
WHO | 2020 | Brief 
https://www.who.int/blueprint/priority-diseases/key-action/liverecovery-save-of-ethical-standards-
for-research-during-public-health-emergencies.pdf?ua=1 
This brief summarises key universal ethical standards to be applied to research during public 
health emergencies. 
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1. Tracking COVID-19 cases 
Global 
WHO COVID-19 daily situation reports 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 
An interactive web-based dashboard to track COVID-19 in real time 
https://www.nice.org.uk/covid-19 
Live data tracker: sex-disaggregated COVID-19 data from the 25 most-affected countries 
http://globalhealth5050.org/covid19 
Africa 
Coronavirus in Africa Tracker: How many covid-19 cases & where? 
https://africanarguments.org/2020/03/23/coronavirus-in-africa-tracker-how-many-cases-and-
where-latest/ 
UK 
COVID-19: PHE track coronavirus cases in the UK 
https://www.gov.uk/government/publications/covid-19-track-coronavirus-cases 
UK case tracing infographic 
https://www.arcgis.com/apps/opsdashboard/index.html#/f94c3c90da5b4e9f9a0b19484dd4bb14 
2. Online course 
Responding to COVID-19: Real-time training for the coronavirus disease outbreak 
WHO | Available now | multiple self-paced courses 
https://openwho.org/channels/covid-19 
Note that courses are available in English and other languages including French, Portuguese 
and Spanish. 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 23 March 2020 | 3 weeks | 4 hours weekly study | Free 
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https://www.futurelearn.com/courses/covid19-novel-coronavirus 
A reminder that this course is currently running. On this course you will learn what is known 
about the outbreak of COVID-19 (week 1); what the practical implications for responding to 
COVID-19 are (week 2); and what we need to find out about COVID-19 (week 3). 
3. Resource Hubs 
COVID-19: Research ethics 
https://ethicsresource.ringsgenderresearch.org/covid-19-resources/ 
LSTM: COVID-19 
https://www.lstmed.ac.uk/covid-19 
LSHTM: COVID-19 
https://www.lshtm.ac.uk/research/research-action/covid-19 
International Disability Alliance: COVID 19 and the disability movement 
http://www.internationaldisabilityalliance.org/content/covid-19-and-disability-movement 
Africa Centres for Disease Control and Prevention (Africa CDC) 
https://africacdc.org/covid-19/ 
UNICEF: Latest news and updates on coronavirus disease 2019 (COVID-19) 
https://www.unicef.org/coronavirus/covid-19 
Coronavirus: the science explained 
https://coronavirusexplained.ukri.org/en/ 
Social Science in Humanitarian Action: Updates on the novel COVID-19 outbreak 
https://www.socialscienceinaction.org/update-novel-covid-19-outbreak/ 
Special Collection: Coronavirus (COVID-19): evidence relevant to critical care 
https://www.cochrane.org/news/special-collection-coronavirus-covid-19-evidence-relevant-
critical-care 
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NICE UK: Rapid guidelines and evidence reviews  
https://www.nice.org.uk/covid-19 
Imperial College London MRC Centre for Global Infectious Disease Analysis COVID-19 
reports 
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ 
Global research on COVID-19 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncov 
WHO R&D Blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
WHO: Coronavirus disease (COVID-19) outbreak resources 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
Latest information and advice from the UK Government 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public 
CDC COVID-19 Resources 
https://www.cdc.gov/coronavirus/2019-ncov/index.htmlThe Global Health Network Coronavirus 
outbreak knowledge hub 
The Lancet COVID-19 Resource Centre 
https://www.thelancet.com/coronavirus 
Elsevier’s Novel Coronavirus Information Center 
https://www.elsevier.com/connect/coronavirus-information-center 
Cell Press Coronavirus Resource Hub 
https://www.cell.com/2019-nCOV 
Cochrane Special Collections - COVID-19: infection control and prevention measures 
https://www.cochranelibrary.com/collections/doi/SC000040/full 
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The BMJ Coronavirus (covid-19): Latest news and resources 
https://www.bmj.com/coronavirus?int_source=wisepops&int_medium=wisepops&int_campaign=
DAA_CoronaVirus_Jan24 
Johns Hopkins Coronavirus Resource Centre 
https://coronavirus.jhu.edu 
Global Partnership for Sustainable Development – COVID-19 resources 
http://www.data4sdgs.org/resources/covid-19-resources 
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